Riom, France, September 2, 2020 – ANS Biotech, an independent preclinical Contract Research Organization (CRO) specializing in the pharmacology of pain, announces today the appointment of Dr. Philippe Genne to its board of directors. The appointment comes at a time when the company is rolling out a new strategy covering various fields, which will entail the launch of new services and the stepping-up of its international presence, in particular in the United States, Japan and Northern Europe.
Based on his thorough knowledge of the health and biotech ecosystems, Dr. Philippe Genne will actively contribute to the governance of ANS Biotech, especially when it comes to optimizing the management of the business and analyzing strategic growth opportunities both internally and externally in a sector that is constantly evolving. The CRO is active in areas linked to the treatment of pain, such as neurology, rheumatology, gastroenterology, oncology and post-operative pain.
“I am delighted and honored to welcome Philippe Genne onto our board of directors at a time when the company is nurturing great ambitions for growth.” said Dr. François Caussade, President and Chief Executive Officer of ANS Biotech. “The history of Oncodesign, the success of that company and the remarkable career of Philippe as its founder and CEO are all things that inspired me when I founded ANS Biotech. His outstanding knowledge of service providers in the biomedical R&D sector and of the ecosystem in which they operate will prove an excellent asset in boosting the international reputation of ANS Biotech when it comes to the study of pain and its treatment.”
Dr. Philippe Genne is currently the President and CEO of Oncodesign, a company that he founded in 1995, specializing in precision medicine. Dr. Genne is actively involved at all levels of the value chain in the life sciences sector: in 2012, he helped create the AFSSI (French Association of Service and Innovation Companies for the Life Sciences). He is also the Vice President of the SME-VSE section of the Medicen competitiveness cluster for the Greater Paris region.
“I am thrilled to be joining the board of directors at ANS Biotech, a company I have known for a long time, in order to support it on its path towards growth,” said Dr. Philippe Genne. “It will be a pleasure to use my experience to help ANS Biotech make the best possible development decisions. It is a great example of a technology services company that specializes in a treatment area where innovation must be stimulated at all levels.”
After completing a PhD in 1992 and in 1994 obtaining accreditation to conduct research in pharmacology at the University of Burgundy, Dr. Genne, who has authored more than 150 international publications and communications, was appointed head of a program set up by the Swiss company Debiopharm, aimed at developing a molecule to circumvent a chemotherapy resistance mechanism Dr. Genne had identified in his university research. From 1990 to 1998 he was in charge of its development in oncology from the preclinical to the clinical phases (Phase IA).
About ANS Biotech
Founded in 2006 by Dr. François Caussade, ANS Biotech is an independent preclinical CRO specializing in the pharmacology of pain.
It supports the research and development efforts of companies developing drug candidates in the field of human and animal health as well as nutrition.
ANS Biotech offers consulting services and scientific studies based on clinically relevant in vivo models for the study of promising molecules in the treatment of neuropathic, visceral, inflammatory, post-operative and cancer-related pain. In addition, the company created ALGOGram™, a unique proprietary in vivo screening platform enabling rapid and cost-effective exploration of the analgesic efficacy of any type of product in a broad range of indications.
ANS Biotech is a founding member of the Analgesia Partnership excellence cluster and of the Institut Analgesia foundation. The company is certified as per ISO 9001:2015.
Headquartered in Riom, in the Auvergne-Rhône-Alpes region, the company currently has 15 employees.